Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8845490 | 0.98 | MAPT (0.56) | MAPTTP53THRBHPGDCYP1A2 | |
| Ether SCHEMBL8845483 | 0.90 | MAPT (0.50) | MAPTTP53THRBHPGDCYP1A2 | |
| SCHEMBL12326165 | 0.89 | MAPT (0.56) | MAPTTP53THRBHPGDCYP1A2 | |
| SCHEMBL29697785 | 0.89 | MAPT (0.56) | MAPTTP53THRBHPGDCYP1A2 | |
| SCHEMBL456627 | 0.84 | ABCG2 (0.47) | MAPTTP53THRBHPGDKDM4E | |
| SCHEMBL23143211 | 0.83 | MAPT (0.50) | MAPTTP53THRBHPGDCYP1A2 | |
| SCHEMBL6641490 | 0.82 | ESR2 (0.50) | MAPTHPGDCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3972358 | 0.82 | MAPT (0.57) | MAPTHPGDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4533772 | 0.81 | L3MBTL1 (0.62) | MAPTHPGDCYP1A2KDM4EALDH1A1 | |
| SCHEMBL2494112 | 0.81 | MAPT (0.54) | MAPTTP53THRBHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55047642-A | — | — | None | — | — | JP | disclosed |
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4556477-A1 | TGF-BETA INHIBITOR COMPOUND AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4556478-A1 | TGF-BETA INHIBITOR COMPOUND AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-115417797-B | Preparation method of bifenazate | 长沙创新药物工业技术研究院有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-115974727-B | Synthesis method of bifenazate | 青岛前线生物工程有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-115677540-A | Preparation method of bifenazate | 帕潘纳(北京)科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023000616-A1 | METHOD FOR PREPARING BIFENAZATE | 帕潘纳(北京)科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
| CN-115417797-A | Preparation method of bifenazate | 长沙创新药物工业技术研究院有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-113912511-A | Synthesis method of bifenazate intermediate | 广东广康生化科技股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-102344395-A | Synthesis method for bifenazate | UNIV TONGJI | 2012-02-08 | — | — | CN | disclosed |
| WO-2009005459-A1 | PHENYL-1,2, 3,4-TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A PAIN DISORDER | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| US-7033681-B2 | Organic element for electroluminescent devices | EASTMAN KODAK COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| US-20050208329-A1 | Organic element for electroluminescent devices | EASTMAN KODAK COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-6706895-B1 | CHEMICAL INTERMEDIATES FOR BIFENAZATE | UNIROYAL CHEMICAL COMPANY, INC. | 2004-03-16 | — | — | US | disclosed |
| JP-S5547642-A | LIQUID CRYSTAL ESTER COMPOUND | SEIKO EPSON CORP | 1980-04-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | TGFB1, TGFB2, TGFBR1 | MAPT 136/4885TP53 3340/4885THRB 19/4885 |
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | TGFB1, TGFB2, TGFBR2 | MAPT 103/4885TP53 1373/4885THRB 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.